Key result
Spironolactone improved the extent and duration of reactive hyperemia, heart rate variability, and blood pressure control compared to placebo in non-heart failure hemodialysis patients (P<0.05).
Why the study?
Does spironolactone improve endothelial function and heart rate variability in non-heart failure hemodialysis patients?
RCT (n=14)
Does spironolactone improve endothelial function and heart rate variability in non-heart failure hemodialysis patients?
p-value: p=<0.05
Low-dose spironolactone improves surrogate markers of cardiovascular risk, including endothelial function and heart rate variability, in stable hemodialysis patients without heart failure.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for spironolactone in non-HF hemodialysis; leaves open effects on clinical outcomes.
Flevari et al. (2013) conducted an RCT in Non heart failure hemodialysis (n=14). Spironolactone vs. Placebo was evaluated on Endothelial function (extent and duration of reactive hyperemia), heart rate variability, and blood pressure control (p=<0.05). Spironolactone improved the extent and duration of reactive hyperemia, heart rate variability, and blood pressure control compared to placebo in non-heart failure hemodialysis patients (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: